Matthew J. Carter


Matthew J. Carter


Washington, D.C. | 1900 K Street, NW, Washington, DC, United States of America 20006-1110
+1 202 261 3395 | +1 202 261 3333


Matthew J. Carter focuses his practice on corporate and securities matters, with a particular emphasis on representing issuers and investment banks in public and private securities transactions. Mr. Carter has significant experience advising permanent capital vehicles such as business development companies and closed-end funds. In addition, Mr. Carter advises clients on the formation and structuring of investment advisers and private funds. He also represents private equity and strategic buyers and sellers in corporate transactions and advises clients on corporate governance and other general corporate matters.

Prior to joining Dechert, Mr. Carter served as legislative counsel to a member of the United States House of Representatives.

  • PennantPark Floating Rate Capital Ltd. in its acquisition of MCG Capital Corporation.
  • Van Eck Associates Corporation in connection with its pending acquisition of assets from Yorkville ETF Advisors, LLC and Exchange Traded Concepts LLC.
  • Aequitas Capital Management in connection with certain corporate structuring transactions.
  • SailingStone Capital Partners in connection with its formation and separation of its management team from RS Investments.
  • Reorganization and structuring transactions for several investment advisers to provide operational efficiency and effective succession planning.
  • Golub Capital BDC, Inc. in its follow-on offerings of common stock.
  • Underwriters in the initial public offering and follow-on offerings of common stock by Monroe Capital Corporation.
  • Representation of a credit-focused investment manager in the structuring and launch of parallel onshore and offshore investment funds.
  • Buckeye Technologies in its US$1.5 billion sale to Georgia-Pacific LLC.
  • Affiliates of Stripes Group, a leading growth equity firm, in a number of its investments.
  • Switzerland-based Ferring Pharmaceuticals on its acquisition of Cytokine PharmaSciences Inc. and its UK subsidiary Controlled Therapeutics (Scotland) Ltd.
  • Vanderbilt University, B.E., 2003, cum laude
  • Vanderbilt University Law School, J.D., 2010, Law and Business Certificate, Recipient of the Vanderbilt Scholastic Excellence Award: Mergers and Acquisitions Deal Dynamics
  • District of Columbia
  • Texas